The epidemiology of sarcoma.
Zachary Burningham, Mia Hashibe, Logan Spector...
https://pubmed.ncbi.nlm.nih.gov/23036164Actively Recruiting
Phase Not Applicable
Age: 18Years +
All Genders
Healthy Volunteers
ID04224064
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
Led by Institut du Cancer de Montpellier - Val d'Aurelle · Updated on 2025-02-12
158
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Liposarcoma (LPS), the most common type of soft tissue sarcoma, is a rare cancer affecting adults. This research aims to identify a new non-invasive blood test by measuring circulating serine levels to help diagnose and predict the prognosis of well-differentiated and dedifferentiated liposarcomas. Currently, diagnosis relies on detecting Mdm2 gene amplification through a biopsy-based method called FISH, which has limitations such as invasiveness and insufficient representation of tumor diversity. The study involves collecting blood samples from both healthy volunteers and LPS patients. Healthy subjects will provide a single blood sample, while patients will have multiple samples taken: one before surgery, a second about 4 weeks after surgery, and then every 3 months for 18 months. The blood test uses advanced chromatography and mass spectrometry techniques to measure amino acids, including serine, which may reflect tumor presence and activity. Participants will undergo scheduled blood draws and clinical monitoring throughout the study. Researchers will analyze serine levels to assess their accuracy in diagnosing LPS and predicting relapse after surgery. The main outcome is the sensitivity and specificity of serine measurement at 3 months post-surgery, with additional follow-up for relapse-free survival and serine level changes over 18 months. The study is designed to be patient-friendly, aiming to improve diagnosis and prognosis without invasive biopsies.
CONDITIONS
Brief Title
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
Who Can Participate
Age: 18Years +
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Men or women older than 18 years
- Diagnosed with localized well-differentiated or dedifferentiated liposarcoma, or local or distant relapse of these types
- Deep adipocytic tumor larger than 5 cm suggestive of atypical lipomatous tumor
- Accepting blood sample collection
- Signed informed consent
- Healthy subjects must be men or women older than 18 years
- Healthy subjects must accept blood sample collection
- Healthy subjects must sign informed consent
- Healthy subjects matched on sex and age to the liposarcoma patient cohort
You will not qualify if you...
- Receiving neoadjuvant treatment for current cancer
- Not affiliated with the French Social Protection System
- Unable to follow up due to psychological, social, geographic, or family reasons
- Psychiatric illness preventing informed consent or compliance with study procedures
- History of another cancer within 5 years, except in situ breast carcinoma or certain skin cancers
- Pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Single time point for healthy subjects; multiple sampling points for patients over 18 months
Participants undergo blood sampling to measure circulating serine levels for diagnosis.
1 visit for healthy subjects; 1 pre-surgery visit, 1 visit 4 weeks after surgery, then visits every 3 months for 18 months for patients
Long-term Monitoring
Duration - Up to 18 months after surgery
Participants are monitored through blood samples over time to assess prognosis and relapse-free survival.
Visits every 3 months for up to 18 months post surgery for patients
Trial Site Locations
Total: 1 location
1
Institut du Cancer de Montpellier - Val d'Aurelle
Montpellier, France, 34298
Actively Recruiting
Loading map...
Research Team
J
Jean-Pierre BLEUSE, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
The Prognostic Impact of Unplanned Excisions in a Cohort of 728 Soft Tissue Sarcoma Patients: A Multicentre Study.
Maria Anna Smolle, Per-Ulf Tunn, Elisabeth Goldenitsch...
https://pubmed.ncbi.nlm.nih.gov/28108827The effect of an unplanned excision of a soft-tissue sarcoma on prognosis.
C R Chandrasekar, H Wafa, R J Grimer...
https://pubmed.ncbi.nlm.nih.gov/18256089